Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 343

1.

Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome.

Adiels M, Olofsson SO, Taskinen MR, Borén J.

Arterioscler Thromb Vasc Biol. 2008 Jul;28(7):1225-36. doi: 10.1161/ATVBAHA.107.160192. Review.

2.
3.

Catabolism of lipoproteins and metabolic syndrome.

Therond P.

Curr Opin Clin Nutr Metab Care. 2009 Jul;12(4):366-71. doi: 10.1097/MCO.0b013e32832c5a12. Review.

PMID:
19474714
4.

Pathogenesis and management of the dyslipidemia of the metabolic syndrome.

Raal FJ.

Metab Syndr Relat Disord. 2009 Apr;7(2):83-8. doi: 10.1089/met.2008.0079. Review.

PMID:
19400742
5.

Management of dyslipidemia in the metabolic syndrome: recommendations of the Spanish HDL-Forum.

Ascaso J, Gonzalez Santos P, Hernandez Mijares A, Mangas Rojas A, Masana L, Millan J, Pallardo LF, Pedro-Botet J, Perez Jimenez F, Pintó X, Plaza I, Rubiés J, Zúñiga M.

Am J Cardiovasc Drugs. 2007;7(1):39-58. Review. Erratum in: Am J Cardiovasc Drugs. 2007;7(4):302.

PMID:
17355165
6.

Diabetic dyslipidaemia.

Adiels M, Olofsson SO, Taskinen MR, Borén J.

Curr Opin Lipidol. 2006 Jun;17(3):238-46. Review.

PMID:
16680028
7.

Fatty liver, insulin resistance, and dyslipidemia.

Adiels M, Taskinen MR, Borén J.

Curr Diab Rep. 2008 Feb;8(1):60-4. Review.

PMID:
18367000
8.

Dyslipidemia of the metabolic syndrome.

Ruotolo G, Howard BV.

Curr Cardiol Rep. 2002 Nov;4(6):494-500. Review.

PMID:
12379172
9.

Insulin resistance, the insulin resistance syndrome, and cardiovascular disease.

Reaven GM.

Panminerva Med. 2005 Dec;47(4):201-10. Review.

PMID:
16489319
10.

Type 2 diabetes as a lipid disorder.

Taskinen MR.

Curr Mol Med. 2005 May;5(3):297-308. Review.

PMID:
15892649
11.

Cardiovascular disease risk of type 2 diabetes mellitus and metabolic syndrome: focus on aggressive management of dyslipidemia.

Falko JM, Moser RJ, Meis SB, Caulin-Glaser T.

Curr Diabetes Rev. 2005 May;1(2):127-35. Review.

PMID:
18220588
12.

Mechanisms of hepatic very low-density lipoprotein overproduction in insulin resistance.

Adeli K, Taghibiglou C, Van Iderstine SC, Lewis GF.

Trends Cardiovasc Med. 2001 Jul;11(5):170-6. Review.

PMID:
11597827
13.

Diabetic dyslipidemia and atherosclerosis: evidence from clinical trials.

Farmer JA.

Curr Atheroscler Rep. 2007 Aug;9(2):162-8.

PMID:
17877926
14.

Lipid and lipoprotein dysregulation in insulin resistant states.

Avramoglu RK, Basciano H, Adeli K.

Clin Chim Acta. 2006 Jun;368(1-2):1-19. Epub 2006 Feb 9. Review.

PMID:
16480697
15.

[Atherogenic dyslipidemia and the metabolic syndrome: pathophysiological mechanisms].

Zák A, Slabý A.

Cas Lek Cesk. 2008;147(9):459-70. Review. Czech.

PMID:
18988488
16.

Dyslipidemia in the metabolic syndrome: clinical implications and management.

Hafidh SA, Lavie CJ, Burns BP, Khan SS, Alpert MA.

Minerva Cardioangiol. 2006 Apr;54(2):215-27. Review.

PMID:
16778753
17.

Multiple factors and pathways involved in hepatic very low density lipoprotein-apoB100 overproduction in Otsuka Long-Evans Tokushima Fatty rats.

Qin B, Anderson RA, Kuzuya T, Kitaura Y, Shimomura Y.

Atherosclerosis. 2012 Jun;222(2):409-16. doi: 10.1016/j.atherosclerosis.2012.03.033. Epub 2012 Apr 11.

PMID:
22546076
18.

Nuclear magnetic resonance lipoprotein abnormalities in prediabetic subjects in the Insulin Resistance Atherosclerosis Study.

Festa A, Williams K, Hanley AJ, Otvos JD, Goff DC, Wagenknecht LE, Haffner SM.

Circulation. 2005 Jun 28;111(25):3465-72.

19.

Diabetic dyslipidaemia: from basic research to clinical practice.

Taskinen MR.

Diabetologia. 2003 Jun;46(6):733-49. Epub 2003 May 28. Review.

PMID:
12774165
20.

Liver fat in the pathogenesis of insulin resistance and type 2 diabetes.

Yki-Järvinen H.

Dig Dis. 2010;28(1):203-9. doi: 10.1159/000282087. Epub 2010 May 7. Review.

PMID:
20460912

Supplemental Content

Support Center